Efficacy of Faviprevir in COVID-19 Treatment

Phase 2

Completed

• Conditions: COVID
• Interventions: Drug: Favipiravir; Drug: Chloroquine

• Registration Number: NCT04351295
• Lead Sponsor: Tanta University

Brief Summary

Faviprevir in COVID-19 treatment

Detailed Description

Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 treatment

Study Timeline

• Study First Submitted: 2020-04-15
• Study First Submitted QC: 2020-04-15
• Study First Posted: 2020-04-17
• Study Start: 2020-04-20
• Primary Completion: 2020-09-28
• Study Completion: 2020-09-28
• Status Verified: 2021-10
• Last Update Submitted: 2021-10-29
• Last Update Posted: 2021-11-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 92

Inclusion Criteria

• Patients with covid 19

Exclusion Criteria

• Allergy or contraindications to faviprevir

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Faviprevir	Favipiravir	Faviprevir
chloroquine	Chloroquine	chloroquine

Primary Outcome Measures

Name	Time	Method
Number of patients with mortality or need for mechanical ventilation	6 months	Number of patients with mortality or need for mechanical ventilation

Trial Locations

Locations (1)

Tanta University, Ainshams University; 🇪🇬 Tanta, Egypt